CYT006-AngQb, a vaccine against hypertension targeting angiotensin II, reduces early-morning and day-time blood pressure by Tissot, A, Nussberger, J, Maurer, P, Stocker, H, Pfister, T, Wagner, F, Mueller, P, Jennings, G, Bachmann, M

Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. by Klimek, L, Willers, J, Hammann-Haenni, A, Pfaar, O, Stocker, H, Mueller, P, Renner, W, Bachmann, M

Vaccination against angiotensin II reduces day-time ambulatory blood pressure: Results of a randomized placebo-controlled phase IIA study with CYT006-ANGQB by Tissot, A, Maurer, P, Nussberger, J, Wagner, F, Pfister, T, Stocker, H, Mueller, P, Jennings, G, Bachmann, M

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. by Tissot, A, Maurer, P, Nussberger, J, Sabat, R, Pfister, T, Ignatenko, S, Volk, H, Stocker, H, Müller, P, Jennings, G, Wagner, F, Bachmann, M

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. by Beeh, K, Kanniess, F, Wagner, F, Schilder, C, Naudts, I, Hammann-Haenni, A, Willers, J, Stocker, H, Mueller, P, Bachmann, M, Renner, W